格隆汇10月15日｜思创医惠公告，第三季度营收为5879.51万元，同比下降64.93%；净利润为4706.93万 元，同比增长177.42%。前三季度营收为6.04亿元，同比增长6.95%；净利润亏损476.22万元，同比扭 亏，增长98.32%。 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-100 思创医惠科技股份有限公司 第六届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、董事会会议审议情况 1、审议通过了《关于<2025 年第三季度报告>的议案》 经与会董事审议，一致认为公司《2025 年第三季度报告》包含的信息公允、 全面、真实地反映了本报告期的财务状况和经营成果等事项，所披露的信息真实、 准确、完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案已经公司董事会审计委员会审议通过。 一、董事会会议召开情况 思创医惠科技股份有限公司（以下简称"公司"）第六届董事会第十一次会 议于 2025 年 10 月 14 日在温州市苍南县灵溪镇春晖路 433-505 号公投大楼会议 室以现场表决和通讯表决相结合的方式召开。会议通知于 2025 年 10 月 11 日通 过电子邮件、电话方式送达各位董事。本次会议应出席董事 7 人，实际出席董事 7 人。会议由董事长许益冉先生召集并主持，公司高级管理人员列席了会议。本 次会议的召集、召开和表决程序符合《中 ...

思创医惠公告，第三季度营收为5879.51万元，同比下降64.93%；净利润为4706.93万元，同比增长 177.42%。前三季度营收为6.04亿元，同比增长6.95%；净利润亏损476.22万元，同比扭亏，增长 98.32%。 ...

[Report Statement and Disclaimer](index=1&type=section&id=Report%20Statement%20and%20Disclaimer) This section outlines the company's commitment to the accuracy and completeness of its quarterly report and confirms the unaudited status of the financial statements - The Board of Directors, directors, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, free from false records, misleading statements, or major omissions, and assume individual and joint legal responsibility[3](index=3&type=chunk) - The company's principal, head of accounting, and head of accounting department declare and guarantee the truthfulness, accuracy, and completeness of the financial information in the quarterly report[3](index=3&type=chunk) - The financial report for this period is unaudited[4](index=4&type=chunk)[26](index=26&type=chunk) [Major Financial Data](index=2&type=section&id=Major%20Financial%20Data) This section presents key financial data, including accounting figures, financial indicators, and non-recurring gains and losses, along with explanations for significant changes [Major Accounting Data and Financial Indicators](index=2&type=section&id=Major%20Accounting%20Data%20and%20Financial%20Indicators) The company's Q3 operating revenue significantly decreased by **64.93%** year-on-year, while net profit attributable to shareholders increased by **177.42%**; year-to-date operating revenue grew by **6.95%**, and net profit attributable to shareholders significantly increased by **98.32%** but remained negative, with total assets and equity attributable to shareholders both declining Key Accounting Data and Financial Indicators (Current Reporting Period) | Item | Current Reporting Period (RMB) | Change from Prior Year (%) | | :--- | :--- | :--- | | Operating Revenue | 58,795,121.13 | -64.93% | | Net Profit Attributable to Shareholders of the Listed Company | 47,069,312.46 | 177.42% | | Net Profit Attributable to Shareholders of the Listed Company, Excluding Non-Recurring Gains and Losses | -95,132,022.26 | -51.46% | | Basic Earnings Per Share (RMB/share) | 0.05 | 183.33% | | Diluted Earnings Per Share (RMB/share) | 0.05 | 183.33% | | Weighted Average Return on Net Assets | -73.00% | -65.85% | Key Accounting Data and Financial Indicators (Year-to-Date) | Item | Year-to-Date (RMB) | Change from Prior Year (%) | | :--- | :--- | :--- | | Operating Revenue | 603,818,696.74 | 6.95% | | Net Profit Attributable to Shareholders of the Listed Company | -4,762,164.09 | 98.32% | | Net Profit Attributable to Shareholders of the Listed Company, Excluding Non-Recurring Gains and Losses | -157,687,268.14 | 45.03% | | Net Cash Flow from Operating Activities | 34,036,713.51 | 2,570.50% | | Basic Earnings Per Share (RMB/share) | 0.00 | 100.00% | | Diluted Earnings Per Share (RMB/share) | 0.00 | 100.00% | | Weighted Average Return on Net Assets | -82.28% | -25.76% | Key Accounting Data and Financial Indicators (End of Reporting Period) | Item | End of Current Reporting Period (RMB) | End of Prior Year (RMB) | Change from Prior Year (%) | | :--- | :--- | :--- | :--- | | Total Assets | 1,008,557,511.94 | 2,189,795,268.31 | -53.94% | | Total Equity Attributable to Shareholders of the Listed Company | 577,757,734.32 | 579,788,934.61 | -0.35% | [Non-Recurring Gains and Losses Items and Amounts](index=2&type=section&id=Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses amounted to **RMB 142,201,334.72** for the current period and **RMB 152,925,104.05** year-to-date, primarily driven by gains from the disposal of non-current assets, including land, buildings, and equity of Yihui Technology Non-Recurring Gains and Losses Items and Amounts | Item | Amount for Current Period (RMB) | Amount Year-to-Date (RMB) | Notes | | :--- | :--- | :--- | :--- | | Gains and Losses from Disposal of Non-Current Assets | 141,896,892.28 | 149,983,086.27 | Includes sale of Yihui Technology's land, buildings, and equity | | Government Grants Recognized in Current Profit or Loss | 596,650.74 | 3,732,253.61 | | | Gains and Losses from Changes in Fair Value of Financial Assets and Liabilities Held by Non-Financial Enterprises, and Gains and Losses from Disposal of Financial Assets and Liabilities | 0 | -1,327,669.66 | | | Gains and Losses from Entrusted Investments or Asset Management | 0 | 1,422,599.28 | | | Other Non-Operating Income and Expenses | -267,089.52 | -858,861.01 | | | Less: Income Tax Impact | 25,118.99 | 25,677.28 | | | Impact on Minority Interests (After Tax) | -0.21 | 627.16 | | | Total | 142,201,334.72 | 152,925,104.05 | -- | - Gains and losses from disposal of non-current assets primarily resulted from the net proceeds of **RMB 8,348,898.01** from the sale of Yihui Technology's land, buildings, and facilities in Binjiang District, and **RMB 141,284,624.17** from the sale of Yihui Technology equity[6](index=6&type=chunk) [Changes and Reasons for Major Accounting Data and Financial Indicators](index=3&type=section&id=Changes%20and%20Reasons%20for%20Major%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, multiple balance sheet, income statement, and cash flow statement items experienced significant changes, with asset and liability items largely decreasing due to the deconsolidation of Yihui Technology, while investment income and asset disposal gains substantially increased, and net cash flow from operating activities rose significantly due to reduced personnel costs - Multiple balance sheet items (e.g., notes receivable, accounts receivable, prepayments, inventories, contract assets, long-term receivables, investment properties, fixed assets, intangible assets) significantly decreased, primarily due to Yihui Technology no longer being consolidated[9](index=9&type=chunk) - Multiple liability items (e.g., accounts payable, contract liabilities, employee compensation payable, taxes payable, other payables, non-current liabilities due within one year, other current liabilities) significantly decreased, primarily due to Yihui Technology no longer being consolidated, with some items also involving repayment of borrowed funds[9](index=9&type=chunk)[10](index=10&type=chunk) - Long-term payables increased by **51.05%**, primarily due to the receipt of asset disposal proceeds[10](index=10&type=chunk) - Taxes and surcharges decreased by **75.41%** year-on-year, primarily due to taxes paid on property disposal in the prior period[10](index=10&type=chunk) - Selling expenses, R&D expenses, and financial expenses decreased by **35.39%**, **51.29%**, and **50.26%** respectively, primarily due to reduced operating scale, decreased R&D investment in the medical sector, and accrued convertible bond interest in the prior year[10](index=10&type=chunk) - Investment income significantly increased by **11,881.02%** year-on-year, primarily due to gains from the disposal of subsidiary Yihui Technology in the current period[10](index=10&type=chunk) - Net cash flow from operating activities increased by **2,570.50%** year-on-year, primarily due to reduced personnel costs[10](index=10&type=chunk) [Shareholder Information](index=4&type=section&id=Shareholder%20Information) This section details the company's shareholder structure, including the total number of common shareholders, top ten shareholders' holdings, and changes in restricted shares [Total Number of Common Shareholders and Top Ten Shareholders' Shareholdings](index=5&type=section&id=Total%20Number%20of%20Common%20Shareholders%20and%20Top%20Ten%20Shareholders%27%20Shareholdings) As of the end of the reporting period, Cangnan Sijia IoT Smart Partnership (Limited Partnership), Lu Nan, and Yunhailian Holdings Co., Ltd. were the top three shareholders, holding **5.72%**, **5.61%**, and **5.44%** respectively, with all shares of Yunhailian Holdings Co., Ltd. pledged, and some shares of Zhang Lizhong pledged and frozen - As of the end of the reporting period, the total number of common shareholders was **58,359**[12](index=12&type=chunk) Top 10 Shareholders' Shareholdings | Shareholder Name | Shareholder Type | Shareholding Percentage | Number of Shares Held (shares) | Pledged, Marked, or Frozen Status | | :--- | :--- | :--- | :--- | :--- | | Cangnan Sijia IoT Smart Partnership (Limited Partnership) | Domestic Non-State-Owned Legal Person | 5.72% | 63,890,185 | N/A | | Lu Nan | Domestic Natural Person | 5.61% | 62,739,500 | N/A | | Yunhailian Holdings Co., Ltd. | Domestic Non-State-Owned Legal Person | 5.44% | 60,858,803 | Pledged 60,858,803 | | Fang Zhenchun | Domestic Natural Person | 2.11% | 23,546,600 | N/A | | Zhang Lizhong | Domestic Natural Person | 1.65% | 18,450,902 | Pledged 14,415,027, Frozen 18,450,902 | | Cangnan Xinchuang Enterprise Management Partnership (Limited Partnership) | Domestic Non-State-Owned Legal Person | 0.56% | 6,266,866 | N/A | | Hangzhou Botai Investment Management Co., Ltd. | Domestic Non-State-Owned Legal Person | 0.54% | 6,006,776 | N/A | | Liao Yannan | Domestic Natural Person | 0.45% | 5,000,000 | N/A | | Duan Liping | Domestic Natural Person | 0.45% | 5,000,000 | N/A | | Hongtu Innovation Fund - Jiaxing Jingmei Zhonghe Investment Partnership (Limited Partnership) - Hongtu Innovation Hongren No. 86 Single Asset Management Plan | Other | 0.40% | 4,484,304 | N/A | - Mr. Lu Nan, a natural person shareholder of the company, holds **59.02%** equity in Hangzhou Botai Investment Management Co., Ltd., a legal person shareholder[12](index=12&type=chunk) - Shareholder Duan Liping holds **5,000,000 shares** through a margin trading and securities lending account, and Xia Zongshui holds **3,617,100 shares** through a margin trading and securities lending account[13](index=13&type=chunk) [Total Number of Preferred Shareholders and Top Ten Preferred Shareholders' Shareholdings](index=6&type=section&id=Total%20Number%20of%20Preferred%20Shareholders%20and%20Top%20Ten%20Preferred%20Shareholders%27%20Shareholdings) The company has no preferred shareholders - The company has no preferred shareholders[13](index=13&type=chunk) [Changes in Restricted Shares](index=6&type=section&id=Changes%20in%20Restricted%20Shares) During the reporting period, executive restricted shares held by Zhang Lizhong, Peng Jun, and Hu Kaiyan were released on February 17, 2025, while Hangzhou Botai Investment Management Co., Ltd. still holds **4,505,082** IPO restricted shares, with **25%** of its company shares unlocked annually Changes in Restricted Shares | Shareholder Name | Restricted Shares at Beginning of Period (shares) | Restricted Shares Released in Current Period (shares) | Restricted Shares Increased in Current Period (shares) | Restricted Shares at End of Period (shares) | Reason for Restriction | Proposed Release Date | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Zhang Lizhong | 13,838,176 | 13,838,176 | 0 | 0 | Executive Restricted Shares | Released on February 17, 2025 | | Peng Jun | 3,750 | 3,750 | 0 | 0 | Executive Restricted Shares | Released on February 17, 2025 | | Hu Kaiyan | 1,500 | 1,500 | 0 | 0 | Executive Restricted Shares | Released on February 17, 2025 | | Hangzhou Botai Investment Management Co., Ltd. | 4,505,082 | 0 | 0 | 4,505,082 | IPO Restricted Shares | 25% of its shares in the company are unlocked annually | | Total | 18,348,508 | 13,843,426 | 0 | 4,505,082 | -- | -- | [Other Important Matters](index=6&type=section&id=Other%20Important%20Matters) This section covers significant corporate events, including the completion of a major asset sale, termination of fundraising projects, and progress on the proposed change of controlling shareholder [Completion of Major Asset Sale and Related Party Transaction](index=6&type=section&id=Completion%20of%20Major%20Asset%20Sale%20and%20Related%20Party%20Transaction) The company completed the sale of **100%** equity in Yihui Technology to Cangnan Shanhai Digital Technology Co., Ltd. on August 5, 2025, with the target assets transferred and registered, and industrial and commercial change procedures finalized - The company completed the sale of **100%** equity in Yihui Technology to Cangnan Shanhai Digital Technology Co., Ltd. on August 5, 2025[15](index=15&type=chunk) - The target assets have been transferred and registered under Shanhai Digital, and Yihui Technology has completed the industrial and commercial change registration procedures[15](index=15&type=chunk) [Termination of Fundraising Projects and Replenishment of Working Capital](index=7&type=section&id=Termination%20of%20Fundraising%20Projects%20and%20Replenishment%20of%20Working%20Capital) The company terminated three fundraising projects, including the "IoT Smart Healthcare Traceability Management Project" and "Medical Big Data Application R&D Center" from its 2018 non-public offering, and the "Internet + AI Medical Innovation Operation Service Project" from its 2020 convertible bond project, with all remaining funds used to permanently replenish working capital and all special accounts closed - The company terminated the "IoT Smart Healthcare Traceability Management Project" and "Medical Big Data Application R&D Center" from its 2018 non-public offering of shares project[16](index=16&type=chunk) - The company terminated the "Internet + AI Medical Innovation Operation Service Project", "Marketing System Expansion Project", and "New Generation Smart Healthcare Application R&D Project Based on AI and Microservice Cloud Architecture" from its 2020 convertible bond project[16](index=16&type=chunk) - All remaining raised funds were transferred to the company's own capital account on August 15, 2025, and all special accounts for raised funds have been closed[16](index=16&type=chunk) [Progress on Proposed Change of Controlling Shareholder and Actual Controller](index=7&type=section&id=Progress%20on%20Proposed%20Change%20of%20Controlling%20Shareholder%20and%20Actual%20Controller) Mr. Lu Nan, the company's largest shareholder, signed a share transfer agreement with Cangnan County Industrial Construction Investment Co., Ltd. on April 26, 2025, to transfer **5.61%** of his shares, with a supplemental agreement signed on September 1, 2025, which is expected to change the company's controlling shareholder and actual controller - Mr. Lu Nan, the company's largest shareholder, intends to transfer **62,739,500 shares** (representing **5.61%** of the total share capital) to Cangnan County Industrial Construction Investment Co., Ltd. via agreement transfer[17](index=17&type=chunk) - Mr. Lu Nan and Cangnan Jiantou signed a "Supplemental Agreement to the Share Transfer Agreement" on September 1, 2025[17](index=17&type=chunk) - This share transfer is expected to result in a change of the company's controlling shareholder and actual controller[17](index=17&type=chunk) [Quarterly Financial Statements](index=7&type=section&id=Quarterly%20Financial%20Statements) This section presents the company's unaudited quarterly financial statements, including the consolidated balance sheet, income statement, and cash flow statement, along with notes on the first-time adoption of new accounting standards [Financial Statements](index=7&type=section&id=Financial%20Statements) This section includes the company's consolidated balance sheet as of September 30, 2025, and the consolidated income statement and cash flow statement for the period from the beginning of 2025 to the end of the reporting period, reflecting the company's assets, liabilities, equity, income, expenses, and cash flows during the reporting period [Consolidated Balance Sheet](index=7&type=section&id=Consolidated%20Balance%20Sheet) This table provides a detailed overview of the company's financial position, presenting assets, liabilities, and equity as of September 30, 2025 Key Data from Consolidated Balance Sheet (September 30, 2025) | Item | Balance at Period End (RMB) | Balance at Period Beginning (RMB) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 492,649,508.87 | 415,200,644.88 | | Financial Assets Held for Trading | 53,602,850.48 | 205,704,709.66 | | Accounts Receivable | 82,076,433.03 | 395,319,679.02 | | Inventories | 59,361,030.18 | 176,396,663.36 | | Total Current Assets | 703,188,705.15 | 1,290,839,328.94 | | Long-Term Equity Investments | 72,252,216.49 | 104,540,469.97 | | Investment Properties | 13,998,884.70 | 292,351,288.60 | | Fixed Assets | 99,685,323.27 | 346,767,620.14 | | Total Non-Current Assets | 305,368,806.79 | 898,955,939.37 | | Total Assets | 1,008,557,511.94 | 2,189,795,268.31 | | Accounts Payable | 40,449,311.42 | 319,186,637.94 | | Contract Liabilities | 9,033,144.98 | 56,886,458.05 | | Other Payables | 73,411,309.26 | 631,253,933.93 | | Total Current Liabilities | 143,815,057.28 | 1,402,583,357.34 | | Long-Term Payables | 232,211,857.80 | 153,736,323.48 | | Total Liabilities | 417,703,743.44 | 1,600,932,000.91 | | Total Equity Attributable to Parent Company Shareholders | 577,757,734.32 | 579,788,934.61 | | Total Equity | 590,853,768.50 | 588,863,267.40 | | Total Liabilities and Equity | 1,008,557,511.94 | 2,189,795,268.31 | [Consolidated Income Statement from Year Beginning to End of Reporting Period](index=10&type=section&id=Consolidated%20Income%20Statement%20from%20Year%20Beginning%20to%20End%20of%20Reporting%20Period) This table summarizes the company's financial performance, detailing revenues, costs, and profits for the period from January to September 2025 Key Data from Consolidated Income Statement (January-September 2025) | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 603,818,696.74 | 564,563,042.63 | | Total Operating Costs | 711,900,612.78 | 747,741,398.44 | | Selling Expenses | 33,787,538.12 | 52,290,919.15 | | Administrative Expenses | 72,585,253.61 | 82,581,715.07 | | Research and Development Expenses | 42,152,641.88 | 86,530,617.16 | | Financial Expenses | 19,899,543.47 | 40,006,082.67 | | Other Income | 7,417,902.30 | -880,360.81 | | Investment Income | 144,803,779.80 | -1,229,128.03 | | Operating Profit | -3,050,240.86 | -283,283,593.21 | | Total Profit | -3,909,101.87 | -282,852,044.95 | | Net Profit | -6,485,797.26 | -285,718,834.44 | | Net Profit Attributable to Parent Company Shareholders | -4,762,164.09 | -283,640,006.17 | | Basic Earnings Per Share | 0.00 | -0.31 | | Diluted Earnings Per Share | 0.00 | -0.31 | [Consolidated Cash Flow Statement from Year Beginning to End of Reporting Period](index=12&type=section&id=Consolidated%20Cash%20Flow%20Statement%20from%20Year%20Beginning%20to%20End%20of%20Reporting%20Period) This table presents the company's cash inflows and outflows from operating, investing, and financing activities for the period from January to September 2025 Key Data from Consolidated Cash Flow Statement (January-September 2025) | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 34,036,713.51 | 1,274,545.97 | | Net Cash Flow from Investing Activities | 482,422,914.64 | 470,688,133.32 | | Net Cash Flow from Financing Activities | -336,463,972.37 | -476,415,935.60 | | Net Increase in Cash and Cash Equivalents | 181,136,253.08 | -1,697,391.05 | | Cash and Cash Equivalents at Period End | 492,649,508.87 | 351,567,537.33 | - Net cash flow from operating activities significantly increased by **2,570.50%**, primarily due to reduced personnel costs[10](index=10&type=chunk)[24](index=24&type=chunk) - Within cash inflows from investing activities, net cash received from disposal of subsidiaries and other business units was **RMB 230,196,018.20**[24](index=24&type=chunk) - Within cash inflows from financing activities, other cash received related to financing activities was **RMB 630,000,000.00**[25](index=25&type=chunk) [First-Time Adoption of New Accounting Standards](index=13&type=section&id=First-Time%20Adoption%20of%20New%20Accounting%20Standards) The company adopted new accounting standards for the first time in 2025 but did not adjust relevant items in the financial statements at the beginning of the first adoption year - The company adopted new accounting standards for the first time in 2025 but did not adjust relevant items in the financial statements at the beginning of the first adoption year[26](index=26&type=chunk) [Audit Report](index=13&type=section&id=Audit%20Report) The company's Q3 financial report is unaudited - The company's Q3 financial report is unaudited[26](index=26&type=chunk)

Market Overview - On October 15, the AI medical sector rose by 2.05%, with Saili Medical leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Saili Medical (603716) closed at 26.86, up 7.31% with a trading volume of 384,800 shares and a transaction value of 1.02 billion [1] - Meinian Health (002044) closed at 5.43, up 4.42% with a trading volume of 1,534,300 shares and a transaction value of 823 million [1] - Hongbo Pharmaceutical (301230) closed at 33.40, up 3.99% with a trading volume of 33,500 shares and a transaction value of 111 million [1] - Other notable stocks include Electric Science Digital (600850) up 3.79% and Yao Stone Technology (300725) up 3.45% [1] Capital Flow - The AI medical sector saw a net inflow of 189 million from institutional investors, while retail investors experienced a net outflow of 78.98 million [2][3] - Meinian Health had a net inflow of 88.56 million from institutional investors, but a net outflow of 93.20 million from retail investors [3] - Saili Medical also experienced a net inflow of 71.52 million from institutional investors, with retail investors withdrawing 32.95 million [3]

Core Viewpoint - The stock of Sichuang Medical Technology Co., Ltd. has shown a mixed performance in recent trading sessions, with a year-to-date increase of 13.16% but a decline of 10.88% over the past 60 days, indicating volatility in investor sentiment and market conditions [1][2]. Group 1: Stock Performance - As of October 15, Sichuang Medical's stock price increased by 2.08% to 3.44 CNY per share, with a trading volume of 24.76 million CNY and a turnover rate of 0.65% [1]. - The company has seen a net inflow of main funds amounting to 2.37 million CNY, with significant buying activity from large orders [1]. - The stock has appeared on the "Dragon and Tiger List" three times this year, with the most recent occurrence on February 17 [1]. Group 2: Financial Performance - For the first half of 2025, Sichuang Medical reported a revenue of 545 million CNY, reflecting a year-on-year growth of 37.32%, while the net profit attributable to shareholders was -51.83 million CNY, showing a significant increase in losses by 76.74% [2]. - The company's main business revenue composition includes real estate sales (53.84%), business intelligence (39.28%), and smart healthcare (6.87%) [1]. Group 3: Shareholder Information - As of June 30, the number of shareholders for Sichuang Medical was 65,800, a decrease of 10.81% from the previous period, while the average circulating shares per person increased by 12.11% to 16,914 shares [2]. Group 4: Dividend Information - Since its A-share listing, Sichuang Medical has distributed a total of 532 million CNY in dividends, with no dividends paid out in the last three years [3].

Core Viewpoint - Sichuan Medical Technology Co., Ltd. (hereinafter referred to as "the company" or "Sichuan Medical") is under investigation by the Hangzhou Public Security Bureau for suspected fraudulent issuance of securities, with evidence collection initiated [1] Group 1: Company Investigation and Legal Actions - The company received a notice from the Hangzhou Public Security Bureau regarding the collection of evidence related to a fraud case involving securities issuance [1] - The Zhejiang Securities Regulatory Commission previously issued an administrative penalty and market ban against the company, citing that it inflated revenue and profits through false business activities, resulting in a cumulative inflated revenue of 34.93 million yuan and inflated profits of 33.02 million yuan in 2019, which accounted for 20.03% of the total profit for that period [1] - For the period from January to September 2020, the company inflated revenue by 60.96 million yuan and profits by 52.37 million yuan, which constituted 56.81% of the total profit for that period [1] Group 2: Investor Compensation - Investors who purchased Sichuan Medical shares between April 30, 2020, and October 28, 2022, and still hold the shares, may voluntarily register for compensation through the "Sina Investor Rights Protection Platform" [2][3] - The time limit for filing claims related to the securities false statement case is only two months remaining, urging affected investors to act promptly [2]

Core Viewpoint - The article discusses significant legal developments regarding investor compensation lawsuits against Dingxin Communications (603421) and Sichuang Medical (300078) due to false statements and financial misconduct [1][2]. Group 1: Dingxin Communications (603421) - Dingxin Communications has been ordered by the Shandong High Court to pay a total of 32,800.75 yuan in a lawsuit related to false statements, following a previous ruling by the Qingdao Intermediate People's Court [1]. - The company failed to timely disclose significant changes in external conditions affecting its operations, specifically regarding the State Grid's procurement freeze, which had a major impact on its revenue [1]. - The company also did not disclose the disposal of shares by its controlling shareholder and actual controller, which is another basis for potential investor claims [2]. Group 2: Sichuang Medical (300078) - The investor compensation case against Sichuang Medical is ongoing, with a lawsuit filed in Wenzhou Intermediate Court, following previous successful claims by investors [2]. - The company has been found to have fabricated significant false information in its public offering documents and had false records in its annual reports for 2019 and 2020 [3][4]. - Investors who purchased Sichuang Medical shares between April 30, 2020, and October 29, 2022, may still initiate claims, as the case is approaching the statute of limitations [5].

Group 1 - The company announced the convening of its fourth extraordinary general meeting of shareholders for 2025 on September 8, 2025 [2] - The meeting approved several proposals, including the use of part of its idle self-owned funds for cash management [2]

北京天元（杭州）律师事务所 关于思创医惠科技股份有限公司 2025 年第四次临时股东会的法律意见 的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相 应法律责任。 京天股字（2025）第 564 号 本所及经办律师同意将本法律意见作为本次股东会公告的法定文件，随同其 他公告文件一并提交深圳证券交易所（以下简称"深交所"）予以公告，并依法对 出具的法律意见承担责任。 致：思创医惠科技股份有限公司 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对公司 提供的文件和有关事实进行了核查和验证，现出具法律意见如下： 思创医惠科技股份有限公司（以下简称"公司"）2025 年第四次临时股东会（以 下简称"本次股东会"）采取现场投票与网络投票相结合的方式，现场会议于 2025 年 9 月 8 日（星期一）下午 14：45 在公司会议室（浙江省杭州市滨江区月明路 567 号"医惠中心"23 楼会议室）召开。北京天元（杭州）律师事务所（以下简称"本 所"）接受公司聘任，指派本所律师参加本次股东会现场会议，并根据《中华人民 共和国公司法》、《中华人民共和国证券法》（以下简称"《证券法》"）、《上 ...